 |
 |
|
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE
| |
| | |
|
|
Official Publication of the American Academy of Nanomedicine
|
|
|
|
Guide for Authors
Editor-in-Chief
Chiming Wei, MD, PhD, FACC, FAHA
Ellicott City, MD
Co-Editor-in-Chief
Tachung C. Yih,
PhD, PE
Rochester, MI
EDITORIAL OFFICE:
For submission and correspondence related Abstracts, Posters, Conference Summaries,
and Book Reviews:
Nanomedicine
c/o Chiming Wei, MD, PhD
Phone: 443-326-8548
Email: nanomedicine@gmail.com
For all other submissions:
Managing Editor
Alice Landwehr
Tucson, Arizona
nanomedicine@cox.net
PUBLISHER
Elsevier Inc.
360 Park Avenue South
New York, NY 10010-1710
Aims and Scope of the Journal
Nanomedicine: Nanotechnology, Biology, and Medicine
(Nanomedicine)
is an international, peer-reviewed
journal. Each quarterly
issue of
Nanomedicine
presents basic,
clinical, and engineering research in the field of nanomedicine.
Article categories
include basic, diagnostic, experimental, clinical,
engineering, pharmacologic, and toxicologic nanomedicine. In addition,
regular features
will address the commercialization of
nanomedicine advances, ethics in nanomedicine, funding opportunities,
and other topics of interest
to researchers and clinicians. We
invite authors to submit original manuscripts and review articles.
General Policies and Instructions
for Authors
Peer Review
All manuscripts will be evaluated for completeness and adherence
to submission guidelines
and will then undergo a peer-review process.
Provisional or final acceptance is based on originality, scientific accuracy,
relevance,
clarity, and topical balance of the
Journal. Authors
should suggest the names (with contact information) of three potential
reviewers for the manuscript. Every attempt will be made to use
at least one suggested reviewer. A request to submit a revised manuscript
does not guarantee its acceptance, only
that it will be reconsidered by the reviewers. Decisions will be
communicated to the corresponding
author by e-mail.
Conflict of Interest
Authors are required to acknowledge all funding sources that supported
their work as well as
all institutional or corporate affiliations of the authors. Each submission
must also include a publishable statement
on the title page disclosing any commercial
associations, current and within the past five years, that might pose
a potential, perceived,
or real conflict of interest. These include
grants, patent licensing arrangements, consultancies, stock or other
equity ownership, advisory
board memberships, or payments for
conducting or publicizing the study.
When no competing interests are present, include a statement
on the title page.
The editor asks each reviewer to disclose any competing
interests or to recuse oneself if a competing interest might
interfere
with one's objectivity.
National Institutes of Health Public Access Policy
Certain repositories such
as PubMed Central (PMC) are authorized under special arrangement with Elsevier to process and post certain articles such as those funded
by the National Institutes of Health under its Public Access policy (see elsevier.com
for more detail on our policy).
Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying
research reported in their articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months
after final publication. The version of the article provided by Elsevier will include peer-review comments incorporated by the author
into the article. Because the NIH Public Access policy is voluntary, authors may elect not to deposit such articles in PMC. If you
wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to: NIHauthorrequest@elsevier.com.
Requirements for studies involving live human or animal subjects:
For studies that involved human or animal research,
indicate
approval by the institution's human or animal subject review committee
in the Methods section of the manuscript. Include an
additional
statement of the humane care of the animals with animal studies and
a statement of informed consent or exempt classification
by the IRB
with human studies.
Submission of Manuscripts
Manuscripts must be submitted through the Nanomedicine
online submission and review Web site ( http://ees.elsevier.com/nano ). All manuscripts
submitted to the Journal must be
original and must not have been
previously published elsewhere or currently under consideration by
another publication. In an accompanying
letter, authors should state
that the manuscript, or part of it, have not been and will not be submitted
elsewhere for publication.
In an accompanying letter, authors should state that the manuscript, or any part of it, is not and will not be submitted elsewhere for
publication while under consideration by Nanomedicine.
Manuscript Preparation
Submission items include
a cover letter, a list of suggested reviewers, the
manuscript (including title page, abstract, manuscript text, references,
and table/figure
legends), tables, and figures. Revised manuscripts
should also be accompanied by a unique file (separate from the
covering letter) with
responses to reviewers' comments.
The preferred order of files is as follows: cover letter, suggested
reviewers, response to reviews
(revised manuscripts only), manuscript
file(s), table(s), figure(s). Files should be labeled with appropriate and
descriptive file names
(e.g., SmithText.doc, Fig1.eps, Table3.doc).
Upload text, tables and graphics as separate files. Do not import
figures or tables into
the text document and do not upload your text
as a PDF.
Full-length article manuscripts should not exceed 6000 words
in total length
(including title page, abstract, text, references, tables,
and figure legends), or contain more than 10 tables and figures.
Manuscripts
must be typed, double-spaced and assembled in
this order: title page, abstract, text, acknowledgments, references,
figure legends, tables
and figures.
Leave 1-inch margins on all sides. All manuscripts must conform to
"Uniform Requirements for Manuscripts Submitted to Biomedical
Journals" ( http://www.icmje.org ).
PERMISSIONS: If any material has been published previously
(figure, tables, etc),
provide written permission from the copyright
holder to use such material. Authors are responsible for obtaining
permission and payment
of any fees associated with reuse.
TITLE PAGE: The title page should contain these elements: full
title, all authors' names, academic
degrees, and affiliations; short title (not to exceed 50 characters, including
spaces); name and complete address for corresponding author
and address for reprints
if different from correspondence; fax and telephone number and
e-mail address; conflict of interest statement
if applicable; all
sources of support for research.
ABSTRACT: The abstract should not exceed 150 words and should
summarize the content
of the aricle. Insert 3 to 5 key words after the abstract.
TEXT: For Original Articles, the text should include the headings
Background,
Methods, Results, and Discussion. All pages must be
numbered. Abbreviations must be parenthetically notated at first
mention in the text.
Each table and figure must be mentioned in the
text. Reports of studies on humans and animals must indicate that
each study was approved
by an institutional review committee and
the procedures followed were in accordance with institutional guidelines.
Provide generic rather
than trademarked names of drugs.
ACKNOWLEDGMENTS: The acknowledgments section recognizes
substantive contributions of individuals.
The Editorial Office
must receive written, signed consent from each person recognized
in the acknowledgments to be mentioned in the article
because
acknowledgment can imply endorsement of data and conclusions; upload each permission separately in the online system. Do not
include statements of funding, conflicts, or other disclosures in the Acknowledgments; these must appear on the title page.
REFERENCES:
Reference format should conform to that set forth in "Uniform
Requirements for Manuscripts Submitted to Biomedical Journals"
( http://www.icmje.org
) and journal abbreviations should conform
to the style used in the
Cumulated Index Medicus. Cite references,
figures,
and tables in numeric order according to the first mention in
the text. Accuracy of reference data is the responsibility of the
author.
Verify all references against
original
sources. "In press"
citations must have been accepted for publication and the
name of
the journal or book publisher must be included. The style of citation
should be as follows:
Journals: authors' last
names and initials; title of article; journal
name; date; volume number, and inclusive pages (list all authors
when six or fewer; when
seven or more, list six and add et al):
1. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic
imaging with fluorodeoxyglucose
is efficacious in evaluating
malignant pulmonary disease. J Thorac Cardiovasc Surg
1999;117:719-27.
2. Lytle BW, Blackstone EH, Loop
FD, Houghtaling PL, Arnold JH,
Akhrass R, et al. Two internal thoracic artery grafts are better than
one. J Thorac Cardiovasc Surg 1999;117:855-72.
Books: authors' last names and initials; chapter title, editor's
name, book title, edition, city, publisher, date, and pages:
1. Mollnes TE. Analysis of in vivo complement activation: In:
Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors.
Weir's handbook
of experimental immunology. Volume 78, 5th
ed. Boston: Blackwell Science; 1997, p. 1-8.
Unpublished data and personal communications
should be cited only
in the text, not as a numbered reference. Authors wishing to cite
unpublished material must have a letter of permission
from the originator
of the communication to do so. This letter should be submitted
with the manuscript.
FIGURES: Figures must be
of professional quality. When possible,
please use first-generation artwork. Figures are
encouraged in electronic format. Figures may
be black and white line art, graphs, halftones
(photographs), or color. Be sure that figures are submitted in .tif or .eps format. Line
art (black lines on a white background) must have a minimum resolution of 1,000 dpi. Combination line art (eg, line art with gray fill
patterns) must be created at 500 dpi. Black and white or color photographs must have a minimum resolution of 300 dpi.
Produce images
near to the desired size of the printed version.
Illustrations should be saved at the recommended resolution setting
and sized as close
to a column width (3 to 4 inches) as possible.
Create figures in scale with each other to the extent possible. Avoid
background gridlines
and other formatting that do not convey information
(eg, superfluous use of 3-dimensional formatting, background
shadings). Use uniform
lettering and sizing of all original artwork.
As a general rule the lettering on the artwork should have a finished,
printed size of
7 points. Smaller lettering will yield barely legible
text. Recommended font choices include Arial, Helvetica, or
Symbol. Labeling of
multipart figures (eg, A, B, C...) should use capital letters only and should be done
consistently, preferably using uppercase type (Arial,
Helvetica or
Universe, 11 or 12 points) in the lower-right corner of the figure.
Avoid headings on the figure when possible. Additional
information on
preparation of electronic artwork can be found in the Artwork
Instructions available at http://authors.elsevier.com/
. For best results,
please follow these guidelines carefully. Publication of color illustrations
in the print Journal will be charged
to the author.
TABLES: Table numbers should be Arabic, followed by a period
and a brief title. Begin each table on a separate page.
Use same size
type as in text where possible. Supply a brief heading for each
column. Do not use vertical lines between columns. Use
horizontal
lines above and below the column headings and at the bottom of the
table only. Use extra space to delineate sections within
the table.
Abbreviations used in the table must be defined in a footnote to the
table. Indicate footnotes in this order:  .
VIDEOS: Nanomedicine is pleased to offer hosting of videos! Authors are encouraged to submit videos that give
readers a fuller understanding of the article. Supplementary movies or animation files that supplement a submitted article should be
provided in one of the following preferred formats: .mpg, .mov, .avi, or .gif. All videos are subject to peer review. For more details,
please visit http://www.elsevier.com/wps/find/authorsview.authors/movies_animations.
Content Types:
- BASIC NANOMEDICINE INVESTIGATIONS: Studies using
nanotechnology to answer basic medical and biologic questions
such as cell
activity, DNA and RNA regulation, intracellular
pathways, and nanosurgery.
- DIAGNOSTIC NANOMEDICINE INVESTIGATIONS: Studies
using nanotechnology for diagnostic research and imaging
development.
- EXPERIMENTAL NANOMEDICINE INVESTIGATIONS:
Studies in
laboratory animal experiments and in vitro experiments
related to nanomedicine.
- CLINICAL NANOMEDICINE INVESTIGATIONS: Studies
in
clinical nanomedical science such as the approach of nanomedicine
to prevent or treat different diseases.
- ENGINEERING NANOMEDICINE
INVESTIGATIONS:
Studies in development of engineering nanomedical technology
in a medical specialty.
- PHARMACOLOGICAL NANOMEDICINE:
Studies in drug
delivery, pharmacologic mechanisms and particles.
- TOXICOLOGY NANOMEDICINE: Studies in side effects and
toxicology.
- COMMERCIALIZATION OF NANOMEDICINE: Information
regarding the commercialization of new products in the field.
- ETHICS
IN NANOMEDICINE: Articles related to the ethical
application of advances in nanomedicine.
- EDITORIAL COMMENTS: Invited articles
or brief editorial
comments that represent opinions of recognized leaders in
nanomedicine research; length should not exceed 3000 words,
and
no more than 20 references should be cited.
- SCIENTIFIC REVIEWS: Review articles of selected important
topics in nanomedicine
research. Length should not exceed
10,000 words (including title page, abstracts, text, references,
tables, and figure legends), and
the article should have no more
than 15 figures. No more than 150 references should be cited,
which may be posted online only.
-
BOOK REVIEWS: Reviews of selected books in nanomedicine,
including books that present innovative concepts and books that
describe state-of-the-art
diagnostic or therapeutic methods or
important advances; Authors should submit books for review to
the Nanomedicine Editorial
Office.
- TECHNICAL NOTES: Length of technical notes should not
exceed 1,200 words, 4 figures, and 10 references.
-
CORRESPONDENCE: Letters to the Editor may not exceed 500
words with 10 references or fewer and one illustration or table.
- MEETING
INFORMATION: Meeting information regarding
upcoming nanomedicine conferences. Please contact Elsevier
advertising department for rates
(212-989-5800).
OFFPRINTS: Offprint order forms will be sent to authors
before articles are published. Reprints in quantity
must be purchased
from the Publisher.
Updated June 2008
|
|
|
|
| |
| | |
|
| |
